AI Article Synopsis
- The text discusses the global issue of multidrug-resistant (MDR) bacteria, particularly focusing on the rise of strains that produce extended-spectrum beta-lactamase (ESBL) and are resistant to fluoroquinolones, often linked to international travel and agricultural antibiotic use.
- It presents a case study of a 25-year-old male who contracted a specific MDR strain, Choleraesuis, after traveling to Thailand, leading to serious health complications.
- This case is significant as it marks the first reported instance of this resistant strain in Europe, highlighting the need for awareness of such pathogens in patients with relevant travel history and biliary tract issues.
Article Abstract
Massive global spread of multidrug-resistant (MDR) spp. expressing extended-spectrum beta-lactamase (ESBL) and additional resistance to fluoroquinolones has often been attributed to high international mobility as well as excessive use of oral antibiotics in livestock farming. However, MDR spp. have not been mentioned as a widespread pathogen in clinical settings so far. We demonstrate the case of a 25-year-old male with primary sclerosing cholangitis who tested positive for MDR serotype Choleraesuis expressing ESBL and fluoroquinolone resistance. The pathogen was supposedly acquired during a trip to Thailand, causing severe fever, cholangitis and pancreatitis. To our knowledge, this is the first report of serotype Choleraesuis in Europe expressing such a multidrug resistance pattern. ESBL resistance of spp. should be considered in patients with obstructive biliary tract pathology and travel history in endemic countries.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360651 | PMC |
| http://dx.doi.org/10.3748/wjg.v23.i11.2086 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of liver transplantation on intestinal and systemic inflammation markers in patients with colitis ulcerosa concomitant with primary sclerosing cholangitis.
Prz Gastroenterol
December 2024
Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, Szczecin, Poland.
Introduction: Primary sclerosing cholangitis (PSC) is an uncommon, chronic liver disease characterised by fibrosis and strictures of a bile ducts, causing cholestasis. In the long term it can lead to complete stenosis leading in turn to liver cirrhosis. In patients with severe form of the disease, the recommended treatment is liver transplantation.
View Article and Find Full Text PDFCausal effect of primary sclerosing cholangitis on diffuse large B-cell lymphoma: A two-sample Mendelian randomized study.
Medicine (Baltimore)
November 2024
Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
The connection between Primary sclerosing cholangitis (PSC) and lymphoma remains uncertain. To address this, Mendelian randomization (MR) was utilized to investigate the potential causal links between PSC and lymphoma. A 2-sample MR analysis was conducted utilizing summary-level data obtained from genome-wide association study datasets.
View Article and Find Full Text PDFLiver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4-/- Mice.
Liver Int
February 2025
Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Background And Aims: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterised by progressive biliary inflammation and fibrosis, leading to liver cirrhosis and cholangiocarcinoma. GPBAR1 (TGR5) is a G protein-coupled receptor for secondary bile acids. In this study, we have examined the therapeutic potential of BAR501, a selective GPBAR1 agonist in a PSC model.
View Article and Find Full Text PDFThe Association Between Primary Sclerosing Cholangitis and Microscopic Colitis: A Systematic Review.
Cureus
December 2024
Internal Medicine, Wayne State University School of Medicine, Dearborn, USA.
The association between primary sclerosing cholangitis (PSC) and microscopic colitis (MC) has been explored in limited studies, suggesting potential shared pathophysiological mechanisms. This systematic review aimed to investigate this relationship by analyzing studies identified through comprehensive searches in PubMed, Embase, and the Cochrane Library. Two studies met the inclusion criteria: a case series of 12 patients and a case report, collectively analyzing 13 cases.
View Article and Find Full Text PDFEffectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis.
Therap Adv Gastroenterol
January 2025
Division of Gastroenterology and Hepatology, Department of Internal Medicine, King Faisal Specialist Hospital and Research Center, P. O. Box 3354, Riyadh 11121, Saudi Arabia.
Background: Inflammatory bowel disease (IBD) occurs in up to 70%-80% of patients with primary sclerosing cholangitis (PSC). Oral vancomycin therapy (OVT) has been reported to be effective in the treatment of IBD associated with PSC (IBD-PSC).
Objectives: To examine the effectiveness and safety of OVT in the treatment of IBD-PSC by performing a systematic review and pooled analysis of the literature.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!